Altogether, our results show that a selective and marked activation of the IFNγ pathway is present in the affected livers of patients with sHLH or MAS who do not present systemic symptoms and do not show peripheral blood laboratory features characteristic of HLH. This evidence concerns the gene IFNG and macrophage activation syndrome.